Megha Mehrotra
Overview
Explore the profile of Megha Mehrotra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
974
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Selzer L, VanderVeen L, Parvangada A, Martin R, Collins S, Mehrotra M, et al.
J Acquir Immune Defic Syndr
. 2024 Sep;
98(1):64-71.
PMID: 39298557
Background: HIV envelope (env) diversity may result in resistance to broadly neutralizing antibodies (bNAbs). Assessment of genotypic or phenotypic susceptibility to antiretroviral treatment is often performed in people with HIV-1...
2.
Avelino-Silva V, Stone M, Bakkour S, Di Germanio C, Schmidt M, Conway A, et al.
Int J Infect Dis
. 2024 Aug;
148:107222.
PMID: 39186969
Background: Exposure to antiretrovirals at or early after HIV acquisition can suppress viral replication and blunt antibody (Ab) responses; a reduced HIV detectability could impact diagnosis and blood donation screening....
3.
Phadte P, Bishnu A, Dey P, M M, Mehrotra M, Singh P, et al.
J Exp Clin Cancer Res
. 2024 Aug;
43(1):222.
PMID: 39123206
Background: The mechanisms enabling dynamic shifts between drug-resistant and drug-sensitive states in cancer cells are still underexplored. This study investigated the role of targeted autophagic protein degradation in regulating ovarian...
4.
Mehrotra M, Phadte P, Shenoy P, Chakraborty S, Gupta S, Ray P
Adv Exp Med Biol
. 2024 May;
1452:65-96.
PMID: 38805125
Epithelial ovarian cancer (EOC) is a complex disease with diverse histological subtypes, which, based on the aggressiveness and course of disease progression, have recently been broadly grouped into type I...
5.
Mukherjee S, Sakpal A, Mehrotra M, Phadte P, Rekhi B, Ray P
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398234
In the original publication [...].
6.
Goyal M, Haythornthwaite J, Jain S, Peterlin B, Mehrotra M, Levine D, et al.
Mindfulness (N Y)
. 2024 Jan;
14(2):406-417.
PMID: 38282695
Objectives: Preventing migraine headaches and improving the quality of life for patients with migraine remains a challenge. We hypothesized intensive meditation training would reduce the disease burden of migraine. Method:...
7.
Panda T, M M, Vaidya S, Chhatar S, Sinha S, Mehrotra M, et al.
Angew Chem Int Ed Engl
. 2023 Jun;
62(38):e202303958.
PMID: 37314332
Even in the modern era of precision medicine and immunotherapy, chemotherapy with platinum (Pt) drugs remains among the most commonly prescribed medications against a variety of cancers. Unfortunately, the broad...
8.
Chakraborty S, Shenoy P, Mehrotra M, Phadte P, Singh P, Rekhi B, et al.
Diagnostics (Basel)
. 2023 Feb;
13(4).
PMID: 36832201
Epithelial ovarian cancer (EOC) is the deadliest gynaecological malignancy and the eighth most prevalent cancer in women, with an abysmal mortality rate of two million worldwide. The existence of multiple...
9.
Andrejko K, Pry J, Myers J, Mehrotra M, Lamba K, Lim E, et al.
Am J Epidemiol
. 2023 Jan;
192(6):895-907.
PMID: 36702469
Concerns about the duration of protection conferred by coronavirus disease 2019 (COVID-19) vaccines have arisen in postlicensure evaluations. "Depletion of susceptibles," a bias driven by differential accrual of infection among...
10.
Mukherjee S, Sakpal A, Mehrotra M, Phadte P, Rekhi B, Ray P
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884426
An active fluidic microenvironment governs peritoneal metastasis in epithelial ovarian cancer (EOC), but its critical functional/molecular cues are not fully understood. Utilizing co-culture models of NIH3T3 cells (differentially overexpressing Jagged1)...